Plain-English translation of NCT05996432 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This early-phase trial is testing whether specialized MRI scans can reliably detect areas in tumors that don't have enough oxygen — a condition called hypoxia. Researchers will compare these MRI results with a special PET scan using an imaging agent called 18F-FMISO to see if the MRI method works accurately. The goal is to develop a simpler, non-invasive way to identify oxygen-poor tumor areas so doctors can adjust radiation therapy to be more effective.
Tumors often contain areas that lack oxygen, and these areas can be harder to treat with standard radiation therapy. Currently, detecting these oxygen-poor regions requires an invasive PET scan. This trial aims to find a simpler MRI-based method that could help doctors personalize treatment plans and improve outcomes for patients with head and neck cancer or brain tumors that have spread.
You likely qualify if…
You likely don't qualify if…
You will undergo two imaging scans: an MRI scan and a PET scan with the imaging agent 18F-FMISO. Researchers will use these scans to measure oxygen levels in your tumor before treatment. If you are being treated with radiation therapy, you may also have follow-up scans three months after treatment to see how the tumor has changed. The study involves a small number of visits for imaging only; you will continue to receive your standard cancer treatment as planned.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States